These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28043438)

  • 1. Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction.
    Weaver FA; Abraham WT; Little WC; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Madershahian N; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Zile MR
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):320-328. PubMed ID: 28043438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
    Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: Long-term outcomes.
    Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
    Eur J Heart Fail; 2024 Apr; 26(4):1051-1061. PubMed ID: 38606555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease.
    Halbach M; Abraham WT; Butter C; Ducharme A; Klug D; Little WC; Reuter H; Schafer JE; Senni M; Swarup V; Wachter R; Weaver FA; Wilks SJ; Zile MR; Müller-Ehmsen J
    Int J Cardiol; 2018 Sep; 266():187-192. PubMed ID: 29705650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction.
    Zile MR; Lindenfeld J; Weaver FA; Zannad F; Galle E; Rogers T; Abraham WT
    J Am Coll Cardiol; 2020 Jul; 76(1):1-13. PubMed ID: 32616150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of chronic carotid baroreceptor activation on arterial stiffness in severe heart failure.
    Gronda E; Brambilla G; Seravalle G; Maloberti A; Cairo M; Costantino G; Lovett E; Vanoli E; Mancia G; Grassi G
    Clin Res Cardiol; 2016 Oct; 105(10):838-46. PubMed ID: 27120329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction.
    Abraham WT; Zile MR; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    JACC Heart Fail; 2015 Jun; 3(6):487-496. PubMed ID: 25982108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-pharmacologic autonomic neuromodulation for treatment of heart failure: A systematic review and meta-analysis of randomized controlled trials.
    Ahmed M; Nudy M; Bussa R; Weigel F; Naccarelli G; Maheshwari A
    Trends Cardiovasc Med; 2024 Feb; 34(2):101-107. PubMed ID: 36202286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta-analysis of randomized controlled trials.
    Coats AJS; Abraham WT; Zile MR; Lindenfeld JA; Weaver FA; Fudim M; Bauersachs J; Duval S; Galle E; Zannad F
    Eur J Heart Fail; 2022 Sep; 24(9):1665-1673. PubMed ID: 35713888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baroreflex activation therapy in patients with heart failure with reduced ejection fraction: a single-centre experience.
    Blanco C; Madej T; Mangner N; Hommel J; Grimm S; Knaut M; Linke A; Winzer EB
    ESC Heart Fail; 2023 Dec; 10(6):3373-3384. PubMed ID: 37667319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baroreflex Activation Therapy in Heart Failure With Reduced Ejection Fraction: Available Data and Future Perspective.
    Halbach M; Fritz T; Madershahian N; Pfister R; Reuter H
    Curr Heart Fail Rep; 2016 Apr; 13(2):71-6. PubMed ID: 26879389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on "Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction".
    Oliveira M
    Rev Port Cardiol; 2015 Dec; 34(12):795-7. PubMed ID: 27099884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term chronic baroreflex activation: persistent efficacy in patients with heart failure and reduced ejection fraction.
    Gronda E; Seravalle G; Trevano FQ; Costantino G; Casini A; Alsheraei A; Lovett EG; Vanoli E; Mancia G; Grassi G
    J Hypertens; 2015 Aug; 33(8):1704-8. PubMed ID: 26132760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Baroreflex activation therapy. A novel interventional approach to treat heart failure with reduced ejection fraction].
    Halbach M; Fritz T; Madershahian N; Pfister R; Reuter H
    Herz; 2015 Nov; 40(7):959-65. PubMed ID: 26525523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany.
    Borisenko O; Müller-Ehmsen J; Lindenfeld J; Rafflenbeul E; Hamm C
    BMC Cardiovasc Disord; 2018 Aug; 18(1):163. PubMed ID: 30092774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac Contractility Modulation and Baroreflex Activation Therapy in Heart Failure Patients.
    Mann JA; Abraham WT
    Curr Heart Fail Rep; 2019 Feb; 16(1):38-46. PubMed ID: 30762177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Restoration of normal sympathetic neural function in heart failure following baroreflex activation therapy: final 43-month study report.
    Dell'Oro R; Gronda E; Seravalle G; Costantino G; Alberti L; Baronio B; Staine T; Vanoli E; Mancia G; Grassi G
    J Hypertens; 2017 Dec; 35(12):2532-2536. PubMed ID: 28816745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States.
    Bisognano J; Schneider JE; Davies S; Ohsfeldt RL; Galle E; Stojanovic I; Deering TF; Lindenfeld J; Zile MR
    BMC Cardiovasc Disord; 2021 Mar; 21(1):155. PubMed ID: 33771104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response by Sex in Patient-Centered Outcomes With Baroreflex Activation Therapy in Systolic Heart Failure.
    Lindenfeld J; Gupta R; Grazette L; Ruddy JM; Tsao L; Galle E; Rogers T; Sears S; Zannad F
    JACC Heart Fail; 2021 Jun; 9(6):430-438. PubMed ID: 33992562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic baroreflex activation: a potential therapeutic approach to heart failure with preserved ejection fraction.
    Georgakopoulos D; Little WC; Abraham WT; Weaver FA; Zile MR
    J Card Fail; 2011 Feb; 17(2):167-78. PubMed ID: 21300307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.